Question Title

* 1. Please indicate how well the program's learning objectives were met by applying the following scale:

  Before After
Your knowledge of high CV risk (post-ACS) patient profiles and the role and place of PCSK9i alirocumab in their treatment pathway
Your knowledge of ODYSSEY OUTCOMES data and their subsequent sub-analysis
Your awareness of the urgency to treat specific high CV risk patient profiles

Question Title

* 2. Activity Evaluation: Please indicate your response to the questions below by applying the following scale (please select your choice):

  Agree Neutral Disagree
The session was appropriate to my practice
This session met my educational needs
The overall e-learning format was effective for learning

Question Title

* 3. Please indicate whether the information presented by the expert was clear and effective (Please select your choice):

  Agree Neutral Disagree
Dr. Shaun Goodman
Dr. Lawrence A. Leiter
Dr. G.B. John Mancini

Question Title

* 4. Did you perceive any degree of bias in any part of the presentation?

  Yes No
Dr. Shaun Goodman
Dr. Lawrence A. Leiter
Dr. G.B. John Mancini

Question Title

* 5. The most valuable insights I learned from this program were:

Question Title

* 6. From what you have learned, what will you be able to apply to your practice?

Question Title

* 7. Please indicate which topics related to this program and therapeutic area that you would like to hear more about in the future:

Question Title

* 8. How did you hear about this program?

Question Title

* 9. Additional comments/feedback:

T